Perceptive Advisors VRNA Position
Exited9-Fund ConvergencePerceptive Advisors exited their position in Verona Pharma plc (VRNA) in Q4 2025, after holding the stock for 8 quarters.
The position was first reported in Q1 2024 and has been tracked across 8 quarterly 13F filings.
VRNA is a convergence signal: 9 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for Ensifentrine 3 mg in 13 days (Apr 29, 2026), making the timing of Perceptive's position particularly relevant.
About Verona Pharma plc
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
Full company profile →Perceptive Advisors VRNA Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Exited | 0 | -524,088 | $0 |
| Q3 2025 | Decreased | 524,088 | -4,983,503 | $55.9M |
| Q2 2025 | Decreased | 5,507,591 | -1,055,749 | $520.9M |
| Q1 2025 | Increased | 6,563,340 | +171,234 | $416.7M |
| Q4 2024 | Increased | 6,392,106 | +76,173 | $296.8M |
| Q3 2024 | Increased | 6,315,933 | +3,882,208 | $181.7M |
| Q2 2024 | Decreased | 2,433,725 | -1,327,851 | $35.2M |
| Q1 2024 | New | 3,761,576 | +3,761,576 | $60.5M |
Frequently Asked Questions
Does Perceptive Advisors own VRNA?
No. Perceptive Advisors exited their position in Verona Pharma plc (VRNA) in Q4 2025. They previously held the stock for 8 quarters.
How many hedge funds own VRNA?
9 specialist biotech hedge funds currently hold VRNA, including RTW Investments, Eventide Asset Management, RA Capital Management and 6 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Perceptive Advisors first buy VRNA?
Perceptive Advisors's position in VRNA was first reported in Q1 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Perceptive Advisors's VRNA position increasing or decreasing?
Perceptive Advisors completely exited their VRNA position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
VRNACompany Page →
All fund holders, insider trades, catalysts, and cash runway
Perceptive AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →